Literature DB >> 3965339

Plasma motilin concentration and interdigestive migrating motor complex in diabetic gastroparesis: effect of metoclopramide.

S R Achem-Karam, A Funakoshi, A I Vinik, C Owyang.   

Abstract

The objective of this study is to determine whether abnormal rhythm and amplitude of the oscillation in plasma motilin concentration are responsible for the abnormal motility observed in patients with diabetic gastroparesis. We also investigated the effect of metoclopramide on plasma motilin concentration and gastrointestinal motility in these patients. In healthy controls, basal plasma motilin concentration fluctuated in phase with the interdigestive migrating motor complex. All patients with diabetic gastroparesis did not have antral phase III activities and had significantly higher basal motilin concentrations, which maintained a normal oscillatory pattern. Administration of metoclopramide initiated antral phase III activities in healthy controls and in patients with diabetic gastroparesis. These were accompanied by a concurrent rise in plasma motilin concentration in healthy controls, contrasting with a fall in plasma motilin concentrations in patients with diabetic gastroparesis. We conclude that diabetic gastroparesis is associated with absence of antral interdigestive migrating motor complex and with elevated plasma motilin concentration with normal cyclic fluctuations. Our studies also show that metoclopramide initiates antral phase III activities in diabetic gastroparesis independent of plasma motilin concentration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965339     DOI: 10.1016/0016-5085(85)90512-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

Review 1.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

2.  Disturbed initiation of gastric interdigestive migrating complexes despite high plasma motilin levels in patients with low gastric pH.

Authors:  M Kusano; T Sekiguchi; O Kawamura; K Kikuchi; K Nakamura; M Mori
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 3.  Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures.

Authors:  J R Malagelada; E Distrutti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

4.  Direct effects of motilin on isolated smooth muscle from various regions of the human stomach.

Authors:  F E Lüdtke; H Müller; K Golenhofen
Journal:  Pflugers Arch       Date:  1989-09       Impact factor: 3.657

5.  Interdigestive gallbladder emptying, antroduodenal motility, and motilin release patterns are altered in cholesterol gallstone patients.

Authors:  M F Stolk; K J Van Erpecum; T L Peeters; M Samsom; A J Smout; L M Akkermans; G P Vanberge-Henegouwen
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

Review 6.  Postoperative ileus.

Authors:  E H Livingston; E P Passaro
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

Review 7.  Gastrointestinal disturbances in diabetes.

Authors:  Manju Chandran; Neelima V Chu; Steven V Edelman
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

8.  Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis--effects of cisapride.

Authors:  R J Fraser; M Horowitz; A F Maddox; J Dent
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

9.  Upper gastrointestinal involvement in diabetes mellitus: study of esophagogastric function.

Authors:  M Pozzi; M Rivolta; M Gelosa; M Capra; G Poggioli; A Bernasconi; G Lomuscio
Journal:  Acta Diabetol Lat       Date:  1988 Oct-Dec

10.  Distribution of peptide-containing nerve fibers in the gastric musculature of patients undergoing surgery for gastroesophageal reflux.

Authors:  D A Wattchow; G G Jamieson; G J Maddern; J B Furness; M Costa
Journal:  Ann Surg       Date:  1992-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.